Conference Coverage

Optimal MPE management requires early pulmonology referral


 

AT CHEST 2016

– About half of patients with symptomatic malignant pleural effusions at McGill University Health Centre in Montreal had unnecessary procedures and hospital admissions before definitive treatment with chemical pleurodesis or indwelling pleural catheters, according to researchers.

Instead of chest taps to relieve symptoms followed by referrals for definitive treatment, some patients got chest tubes – without pleurodesis – after presenting to the emergency department and being referred to radiology; they were then admitted to the hospital for a few days while the tubes were in place. In short, cancer patients were wasting what time they had left on medical care they didn’t need, and incurring unnecessary costs, said lead investigator Benjamin Shieh, MD, formerly at McGill but now an interventional pulmonology fellow at the University of Calgary.

Dr. Benjamin Shieh

Dr. Benjamin Shieh

McGill is a tertiary care center able to perform both definitive procedures, so “we should be a center of excellence. I imagine there are similar situations” at other hospitals, especially those without the resources of McGill, Dr. Shieh said at the annual meeting of the American College of Chest Physicians.

McGill has taken several steps to address the problem, including early ED referral to the pulmonology service and discouraging radiology from placing chest tubes for malignant pleural effusions (MPE). “I think we can avoid a big proportion of hospitalizations for MPE, and certainly a proportion of repeat [ED] visits,” said senior author Anne Gonzalez, MD, an attending pulmonologist at McGill.

Dr. Anne Gonzalez

Dr. Anne Gonzalez

The investigators looked into the issue after noting that a lot of their MPE cases had been hospitalized with chest tubes. They reviewed 72 symptomatic MPE cases in 69 patients treated in 2014 and 2015. Management was ideal in 36 cases (50%), meaning that, prior to definitive treatment, patients had no more than two pleural taps for symptom relief, no more than one ED visit, no chest tubes without pleurodesis, and no hospitalizations. “We thought this would be reasonable to try to achieve for MPE,” since there’s no definition of ideal management, Dr. Shieh said.

Nonideal patients had a mean of 2.5 pleural procedures – almost twice the number in the ideal group – before definitive palliation, with no respiratory consult beforehand. Chest tubes were placed in 27 cases (38%) for an average of 3.7 days; 28 cases (39%) were hospitalized. Nonideal patients were far more likely to present first to the ED, and ED presentations were more likely to get chest tubes and be admitted. All the cases were eventually treated definitively, 68 with indwelling pleural catheters and 4 by thoracoscopic talc insufflation. Time from initial presentation to definitive palliation was about 1 month in both groups. The investigators didn’t consider rate of effusion recurrence, which might help explain why the ideal group wasn’t treated sooner; they might not have needed it. The higher number of ED visits in the nonideal group suggests that they may have had quicker recurrences, and should have been treated sooner, Dr. Gonzalez said.

The patients were 70 years old, on average, and about 60% were women. Lung and breast were the most common cancers.

There was no industry funding for the work, and the investigators had no disclosures.

Recommended Reading

Patients with stage 1 NSCLC more likely to die of other causes in short term
MDedge Hematology and Oncology
Pembrolizumab boosts response but not survival in small study of advanced NSCLC
MDedge Hematology and Oncology
OAK: Atezolizumab grows OS in advanced NSCLC
MDedge Hematology and Oncology
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
MDedge Hematology and Oncology
FDA approves atezolizumab for advanced NSCLC
MDedge Hematology and Oncology
Smoking-attributable cancer mortality highest in Kentucky
MDedge Hematology and Oncology
Lung cancer screening found effective in a community hospital
MDedge Hematology and Oncology
FDA expands indication for pembrolizumab in NSCLC
MDedge Hematology and Oncology
Few non-ICU patients receive palliative care consults
MDedge Hematology and Oncology
Blood assay rapidly identifies lung cancer mutations
MDedge Hematology and Oncology